Signifor Injection
Pasireotide (as diaspartate)
0.3mg/ml
Novartis Pharma AG
| Pack size | 1ml Ampoule x 30 (6’s Box x 5) |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | CITY MEDICAL STORE |
| Retail Price | 8401.50 AED |
Available as:
Indications
Signifor Injection is used for:
For the treatment of Cushing?s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Pasireotide (as diaspartate) :
Mechanism of Action
Pasireotide activates a broad spectrum of somatostatin receptors, exhbiting a much higher binding affinity for somatostatin receptors 1, 3, and 5 than octreotide in vitro, as well as a comparable binding affinity for somatostatin receptor 2. The binding and activation of the somatostatin receptors causes inhibition of ACTH secretion and results in reduced cortisol secretion in Cushing's disease patients. Also this agent is more potent than somatostatin in inhibiting the release of human growth hormone (HGH), glucagon, and insulin.
Note
Signifor 0.3mg/ml Injection manufactured by Novartis Pharma AG. Its generic name is Pasireotide (as diaspartate). Signifor is availble in United Arab Emirates.
Farmaco UAE drug index information on Signifor Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.